全部照片(1)
About This Item
經驗公式（希爾表示法）:
C10H15N5
CAS號碼:
分子量：:
205.26
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24
推薦產品
等級
pharmaceutical primary standard
API 家族
trapidil
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
形式
neat
儲存溫度
2-8°C
SMILES 字串
CCN(CC)c1cc(C)nc2ncnn12
InChI
1S/C10H15N5/c1-4-14(5-2)9-6-8(3)13-10-11-7-12-15(9)10/h6-7H,4-5H2,1-3H3
InChI 密鑰
GSNOZLZNQMLSKJ-UHFFFAOYSA-N
尋找類似的產品？ 前往 產品比較指南
相關類別
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Trapidil EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化／生理作用
Antiplatelet agent; competitive inhibitor of PDGF receptor; phosphodiesterase inhibitor, vasodilator
Trapidil is an antiplatelet agent that acts in part as a phosphodiesterase inhibitor and as a competitive inhibitor of the platelet-derived growth factor (PDGF) receptor. Trapidil, with its vasodilator and NO releasing effect may have some potential to diminish the tissue injury. Trapidil suppresses platelet-derived growth factor (PDGF)-induced vascular smooth muscle cell (VSMC) proliferation by inhibiting Raf-1/extracellular signal-regulated kinase (ERK) via cAMP/protein kinase A (PKA). In addn. to cAMP/PKA activation, trapidil inhibits RhoA/ROCK activation.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
訊號詞
Warning
危險聲明
危險分類
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Russell T Turner et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 25(7), 1637-1649 (2010-03-05)
Chronic hyperparathyroidism (HPT) is a common cause of metabolic bone disease. These studies investigated the underlying cellular and molecular mechanisms responsible for the detrimental actions of elevated parathyroid hormone (PTH) on the skeleton. Bone biopsies from hyperparathyroid patients revealed an
Salih Somuncu et al.
Pediatric surgery international, 24(3), 315-318 (2007-12-07)
We aimed to detect the protective effect of trapidil in ischemia-reperfusion (IR) injury due to ovarian torsion and detorsion. Thirty-two pubertal New Zealand albino rabbits were used. Adnexal torsion was created by rotating the left adnexa including the tubal and
W Sziegoleit et al.
International journal of clinical pharmacology and therapeutics, 45(1), 10-15 (2007-01-30)
In this study the effect of locally administered trapidil on human hand veins was examined. 10 healthy male volunteers aged 20 - 30 years were included. The dorsal hand vein compliance technique was used. In a crossover design the influence
John S Douglas
The American journal of cardiology, 100(5A), 10K-16K (2007-09-28)
Despite significant advances in technology and technique, coronary restenosis remains the primary limitation of percutaneous transluminal coronary angioplasty (PTCA). Among patients undergoing PTCA, between 20% and 50% of patients who do not receive a stent and 10%-30% of those who
Jodie M Dodd et al.
The Cochrane database of systematic reviews, (6)(6), CD006780-CD006780 (2010-06-18)
Pregnancy complications such as pre-eclampsia and eclampsia, intrauterine growth restriction and placental abruption are thought to have a common origin related to abnormalities in the development and function of the placenta. To compare, using the best available evidence, the benefits
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務